Top

Published in:

01-08-2018 | Original Article

Time between diagnosis and surgical treatment on pathological and clinical outcomes in prostate cancer: does it matter?

Authors: Mariana Andozia Morini, Roberto Lodeiro Muller, Paulo César Barbosa de Castro Junior, Rafael José de Souza, Eliney Ferreira Faria

Published in: World Journal of Urology | Issue 8/2018

Abstract

Introduction

Prostate cancer (PC) most of the time presents with an indolent course. Thus, delays in treatment due to any causes might not affect long-term survival and may not affect cancer cure rates.

Purpose

In this study, we evaluated the effect of delay-time between PC diagnosis and radical prostatectomy regarding oncological outcomes: Gleason score upgrade on surgical specimen, pathologic extracapsular extension (ECE) on surgical specimen, and postoperative biochemical recurrence (BCR) on follow-up.

Methods

We evaluated PC patients who underwent radical prostatectomy (RP) regarding clinical and pathological findings and theirs respective interval between diagnosis and surgical treatment measured in days and months. We used univariate and multivariate logistic regression to evaluate the impact of interval-time.

Results

A total of 908 PC patients underwent RP between 2006 and 2014. Mean age was 61.5 years, the mean time-to-surgery was 191 days (> 6 months) and 187 (20.5%) patients had BCR, with a mean follow-up of 44 months. According to our analysis, no statistically significant maximum cut-off time interval between diagnostic biopsy and surgery could be established (p = 0.215). Regardless of interval-time: ≤ 6 months (56.5%), 6–12 months (38.5%), and > 12 months (5.1%) after biopsy, we found no time interval correlated with poor oncological outcomes. This study has several limitations. It was retrospective and had a mean follow-up of 4 years. Additional follow-up is necessary to determine whether these findings will be maintained over time.

Conclusions

We showed that the time between diagnosis and surgical treatment did not affect the oncological outcomes in our study.

Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A et al (2004) Natural history of early, localized prostate cancer. JAMA 291(22):2713–2719CrossRefPubMed

Korets R, Seager CM, Pitman MS, Hruby GW, Benson MC, McKiernan JM (2012) Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis. BJU Int 110(2):211–216CrossRefPubMed

van den Bergh RC, Steyerberg EW, Khatami A, Aus G, Pihl CG, Wolters T et al (2010) Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer 116(5):1281–1290CrossRefPubMed

Sainsbury R, Johnston C, Haward B (1999) Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis. Lancet 353(9159):1132–1135CrossRefPubMed

Roncoroni L, Pietra N, Violi V, Sarli L, Choua O, Peracchia A (1999) Delay in the diagnosis and outcome of colorectal cancer: a prospective study. Eur J Surg Oncol 25(2):173–178CrossRefPubMed

Nam RK, Jewett MA, Krahn MD, Robinette MA, Tsihlias J, Toi A et al (2003) Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. Can J Urol 10(3):1891–1898PubMed

Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr, Terris MK (2006) Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol 175(4):1298–12302 (discussion 302–303) CrossRefPubMed

Boorjian S, Ng C, Munver R, Palese MA, Vaughan ED Jr, Sosa RE et al (2005) Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma. Urology 66(2):283–287CrossRefPubMed

Khan MA, Mangold LA, Epstein JI, Boitnott JK, Walsh PC, Partin AW (2004) Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol 172(5 Pt 1):1835–1839CrossRefPubMed

10.

Graefen M, Walz J, Chun KH, Schlomm T, Haese A, Huland H (2005) Reasonable delay of surgical treatment in men with localized prostate cancer-impact on prognosis? Eur Urol 47(6):756–760CrossRefPubMed

11.

Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33(3):272–277CrossRefPubMed

12.

Harris R, Lohr KN (2002) Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137(11):917–929CrossRefPubMed

13.

Faria EF, Carvalhal GF, Vieira RA, Silva TB, Mauad EC, Tobias-Machado M et al (2011) Comparison of clinical and pathologic findings of prostate cancers detected through screening versus conventional referral in Brazil. Clin Genitourin Cancer 9(2):104–108CrossRefPubMed

14.

Faria EF, Carvalhal GF, Vieira RA, Silva TB, Mauad EC, Carvalho AL (2010) Program for prostate cancer screening using a mobile unit: results from Brazil. Urology 76(5):1052–1057CrossRefPubMed

15.

Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29(9):1228–1242CrossRefPubMed

16.

D’Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D et al (2001) Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 166(6):2185–2188CrossRefPubMed

17.

Corcoran NM, Hong MK, Casey RG, Hurtado-Coll A, Peters J, Harewood L et al (2011) Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int 108(8 Pt 2):E202–E210CrossRefPubMed

18.

Vickers AJ, Bianco FJ Jr, Boorjian S, Scardino PT, Eastham JA (2006) Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence? Cancer 106(3):576–580CrossRefPubMedPubMedCentral

19.

O’Brien D, Loeb S, Carvalhal GF, McGuire BB, Kan D, Hofer MD et al (2011) Delay of surgery in men with low risk prostate cancer. J Urol 185(6):2143–2147CrossRefPubMed

20.

Hsieh FY, Bloch DA, Larsen MD (1998) A simple method of sample size calculation for linear and logistic regression. Stat Med 17(14):1623–1634CrossRefPubMed

21.

Borm GF, Bloem BR, Munneke M, Teerenstra S (2010) A simple method for calculating power based on a prior trial. J Clin Epidemiol 63(9):992–997CrossRefPubMed

22.

Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T et al (2017) Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med 377(2):132–142CrossRefPubMed

23.

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P et al (2016) 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424CrossRefPubMed

24.

Filippou P, Welty CJ, Cowan JE, Perez N, Shinohara K, Carroll PR (2015) Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer. Eur Urol 68(3):458–463CrossRefPubMed

25.

Abern MR, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL et al (2013) Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate 73(4):409–417CrossRefPubMed

26.

Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC et al (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294(4):433–439CrossRefPubMed

27.

Choueiri TK, Chen MH, D’Amico AV, Sun L, Nguyen PL, Hayes JH et al (2010) Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer 116(8):1887–1892CrossRefPubMed

28.

Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC et al (2007) Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 25(13):1765–1771CrossRefPubMed

Title: Time between diagnosis and surgical treatment on pathological and clinical outcomes in prostate cancer: does it matter?
Authors: Mariana Andozia Morini
Roberto Lodeiro Muller
Paulo César Barbosa de Castro Junior
Rafael José de Souza
Eliney Ferreira Faria
Publication date: 01-08-2018
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 8/2018
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2251-5

At a glance: The STEP trials

Springer Medicine

Time between diagnosis and surgical treatment on pathological and clinical outcomes in prostate cancer: does it matter?

Abstract

Introduction

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2018

The effects of intra-arterial chemotherapy on bladder preservation in patients with T1 stage bladder cancer

Fuhrman grading is inappropriate for papillary renal cell carcinoma

Substantial utilization of Facebook, Twitter, YouTube, and Instagram in the prostate cancer community

Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis

Role of urinary tract infection in bladder cancer: a systematic review and meta-analysis

Longer length improvement and more covert incision: a single-center, prospective study of two innovative surgical methods “one stitch” and “four stitch” for pediatric buried penis